We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-11.53 | -3.70% | 299.76 | 299.62 | 299.75 | 312.73 | 297.52 | 310.88 | 2,634,892 | 18:46:01 |
By Ben Glickman
Amgen has received priority review status from the Food and Drug Administration for its biologics license application for a small cell lung cancer treatment.
The Thousand Oaks, Calif.-based pharmaceutical company will get an answer from the FDA on its application in six months, instead of the typical 10 months.
Amgen's BLA is for tarlatamab, a treatment for advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy.
The application is based on the results from a Phase 2 study.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 13, 2023 16:25 ET (21:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions